

Washington University School of Medicine

Digital Commons@Becker

2020-Current year OA Pubs

Open Access Publications

1-1-2022

Clinical and molecular characteristics of a novel rare de novo variant in PPP2CA in a patient with a developmental disorder, autism, and epilepsy

Iris Verbinnen

Sara S Procknow

Lisa Lenaerts

Sara Reynhout

Aujan Mehregan

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

 Part of the [Medicine and Health Sciences Commons](#)

Please let us know how this document benefits you.

Authors

Iris Verbinnen, Sara S Procknow, Lisa Lenaerts, Sara Reynhout, Aujan Mehregan, Chris Ulens, Veerle Janssens, and Katherine A King



OPEN ACCESS

EDITED BY
Ritva Tikkanen,
University of Giessen, Germany

REVIEWED BY
Lila Allou,
Max Planck Institute for Molecular
Genetics, Germany
Jose R. Bayascas,
Universidad Autónoma de Barcelona,
Spain

*CORRESPONDENCE
Veerle Janssens,
veerle.janssens@kuleuven.be
Katherine A. King,
abell_k@wustl.edu

[†]These authors have contributed equally
to this work

SPECIALTY SECTION
This article was submitted to Molecular
and Cellular Pathology,
a section of the journal
Frontiers in Cell and Developmental
Biology

RECEIVED 02 October 2022
ACCEPTED 08 November 2022
PUBLISHED 30 November 2022

CITATION
Verbinnen I, Procknow SS, Lenaerts L,
Reynhout S, Mehregan A, Ulens C,
Janssens V and King KA (2022), Clinical
and molecular characteristics of a novel
rare *de novo* variant in *PPP2CA* in a
patient with a developmental disorder,
autism, and epilepsy.
Front. Cell Dev. Biol. 10:1059938.
doi: 10.3389/fcell.2022.1059938

COPYRIGHT
© 2022 Verbinnen, Procknow, Lenaerts,
Reynhout, Mehregan, Ulens, Janssens
and King. This is an open-access article
distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Clinical and molecular characteristics of a novel rare *de novo* variant in *PPP2CA* in a patient with a developmental disorder, autism, and epilepsy

Iris Verbinnen^{1,2†}, Sara S. Procknow^{3†}, Lisa Lenaerts¹,
Sara Reynhout^{1,2}, Aujan Mehregan⁴, Chris Ulens⁴,
Veerle Janssens^{1,2*} and Katherine A. King^{3*}

¹Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Leuven, Belgium, ²KU Leuven Brain Institute (LBI), Leuven, Belgium, ³Division of Genetics and Genomic Medicine, Department of Pediatrics, Washington University in St. Louis, St. Louis, MO, United States, ⁴Laboratory of Structural Neurobiology, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Leuven, Belgium

PP2A-related (neuro) developmental disorders are a family of genetic diseases caused by a heterozygous alteration in one of several genes encoding a subunit of type 2A protein phosphatases. Reported affected genes, so far, are *PPP2R5D*, encoding the PP2A regulatory B56 δ subunit; *PPP2R1A*, encoding the scaffolding A α subunit; and *PPP2CA*, encoding the catalytic C α subunit—in that order of frequency. Patients with a pathogenic *de novo* mutation in one of these genes, in part, present with overlapping features, such as generalized hypotonia, intellectual and developmental delay, facial dysmorphologies, seizures, and autistic features, and, in part, with opposite features, e.g., smaller versus larger head sizes or normal versus absent corpus callosum. Molecular variant characterization has been consistent so far with loss-of-function or dominant-negative disease mechanisms for all three affected genes. Here, we present a case report of another *PPP2CA*-affected individual with a novel *de novo* missense variant, resulting in a one-amino acid substitution in the C α subunit: p.Cys196Arg. Biochemical characterization of the variant revealed its pathogenicity, as it appeared severely catalytically impaired, showed mildly affected A subunit binding, and moderately decreased binding to B/B55, B $''$ /PR72, and all B56 subunits, except B56 γ 1. Carboxy-terminal methylation appeared unaffected, as was binding to B $'''$ /STRN3—all being consistent with a partial loss of function. Clinically, the girl presented with mild-to-moderate developmental delay, a full-scale IQ of 83, mild dysmorphic facial features, tonic-clonic seizures, and autistic behaviors. Brain MRI appeared normal. We conclude that this individual falls within the milder end of the clinical and molecular spectrum of previously reported *PPP2CA* cases.

KEYWORDS

PP2A-related neurodevelopmental disorders, *de novo* mutation, *PPP2CA*, epilepsy, autism (ASD), developmental delay, case report

1 Introduction

PP2A-related neurodevelopmental disorders (NDDs) are a group of rare genetic diseases characterized by heterozygous *de novo* mutations in *PPP2CA* (Reynhout et al., 2019) (OMIM: #618354), *PPP2R1A* (Houge et al., 2015; Lenaerts et al., 2020; Douzgou et al., 2022) (OMIM: #616362), or *PPP2R5D* (Houge et al., 2015; Loveday et al., 2015; Shang et al., 2016; Mirzaa et al., 2019; Oyama et al., 2022) (OMIM: #616355). These three PP2A genes belong to nineteen human genes encoding the protein phosphatase 2A (PP2A) family of Ser/Thr phosphatases (Janssens and Goris, 2001; Lambrecht et al., 2013), a group of dephosphorylating enzymes with pleiotropic functions in cell signaling and organismal physiology (Janssens and Goris, 2001; Reynhout and Janssens, 2019). Specifically, in the brain, PP2A phosphatases regulate cortical development, synaptic transmission, hippocampus-dependent memory, dopaminergic signaling, and tau phosphorylation (Sandal et al., 2021; Verbinnen et al., 2021). Structurally, PP2A phosphatases comprise at least two subunits: a catalytic C and a scaffolding A subunit, which, in the majority of cases, additionally bind to a third, regulatory B subunit. Through these B subunits, trimeric PP2A complexes achieve their substrate specificity, regulation, subcellular localization, and tissue-specific expression (Slupe et al., 2011; Lambrecht et al., 2013). Despite this major structural complexity, PP2A-related NDDs are characterized by alterations in just a subset of PP2A holoenzymes, and the molecular characterization of *PPP2CA* (encoding the catalytic C α subunit), *PPP2R1A* (encoding the scaffolding A α subunit), and *PPP2R5D* (encoding the regulatory B56 δ subunit) variants have been consistent so far with a loss-of-function mechanism for most, if not, all of them (Houge et al., 2015; Reynhout et al., 2019; Lenaerts et al., 2020; Oyama et al., 2022). Although PP2A affected individuals exhibit common clinical features, including hypotonia, developmental delay (DD) (motoric skills, speech), intellectual disability (ID), differences in brain size, autism (ASD), and seizures, they also show a broad heterogeneity in the severity of their presentation—within individuals affected in different PP2A genes, as well as within individuals affected in the same PP2A gene. In addition, the frequency by which a PP2A gene alteration occurs within the general population is significantly different between genes, with most cases so far discovered for *PPP2R5D* and *PPP2R1A*.

Here, we describe a new case of a currently 18-year-old girl with a developmental disorder, autistic features, epilepsy, and a novel, *de novo* pathogenic variant of *PPP2CA*. Based on 16 previously published individuals, the *PPP2CA*-related disorder has a rather heterogeneous clinical presentation, with mildly to severely affected individuals, and with 15 different reported pathogenic variants dispersed throughout the protein

or the gene (Reynhout et al., 2019). Based on the clinical and molecular data described below, we find that this new case falls well within the spectrum of previously reported *PPP2CA* cases.

2 Materials and methods

2.1 Generation of the *PPP2CA* p.Cys196Arg variant

The coding region of wild-type (WT) Ca complementary DNA (cDNA) was cloned into an N-terminal HA-tag eukaryotic expression vector (pMB001) using *XbaI/BamHI* sites. The mutated *PPP2CA* construct was directly generated from this plasmid by polymerase chain reaction (PCR)-based site-directed mutagenesis (Stratagene) with *Pwo* polymerase (Roche Applied Science) and oligonucleotides (IDT) containing the desired point mutations. Forward and reverse primer sequences were 5'-CCATGAGGGTCCAATGCGTGA CTTGCTGTGGTC-3' and 5'-GACCACAGCAAGTCACGC ATTGGACCCTCATGG-3', respectively. Introduction of the variant was verified by Sanger sequencing (LGC Genomics).

2.2 Cellular PP2A binding assays

HEK293T cells (ATCC, characterized by short tandem repeat profiling and mycoplasma-free) were transfected with PEI or PEI MAX transfection reagent using the standard protocols. All GFP-B-type subunit expression vectors have previously been described (Janssens et al., 2003; Houge et al., 2015; Haesen et al., 2016). The GFP expression plasmid, pEGFP-C1, was from Clontech. Seventy-two hours post-transfection, cells were rinsed with phosphate buffered saline (PBS), lysed in 150 μ l NET buffer (50 mM Tris.HCl pH 7.4, 150 mM NaCl, 15 mM EDTA, and 1% Nonidet P-40) containing protease and phosphatase inhibitor cocktail (Roche Applied Science), and centrifuged for 15 min at 13,000 g. For binding assays with GFP-STRN3, no phosphatase inhibitors were added. If the experiment required the measurement of phosphatase activity, Tris buffered saline (TBS) was used instead of PBS, and phosphatase inhibitors were omitted from the lysis buffer.

For pull-down experiments, lysates were incubated at 4°C for 1 h with 700 μ l NENT100 buffer (20 mM Tris.HCl pH 7.4, 1 mM EDTA, 0.1% Nonidet P-40, 25% glycerol, 100 mM NaCl) containing 1 mg/ml bovine serum albumin and 30 μ l anti-HA-Agarose beads (Sigma-Aldrich, for HA pull-down) or 30 μ l GFP-trap-A beads (ChromoTek, for GFP pull-down). Beads were washed three times with 1 ml NENT300 (containing 300 mM NaCl) and two times with 1 ml NENT150 (containing 150 mM NaCl). Bound proteins were eluted in 2 \times NuPage sample buffer (Invitrogen) and boiled for subsequent analysis by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on 4–12% (w/v) Bis-Tris gels (Thermo Fisher Scientific) and Western blotting.

Membranes were blocked in 5% milk in TBS/0.1% Tween-20 for 1 h at room temperature and incubated with the primary antibody overnight at 4°C. Primary mouse monoclonal antibodies were anti-HA (clone HA-7, Sigma-Aldrich), anti-GFP (B-2) (sc-9996), anti-PP2A-A subunit (clone C5.3D10, generously supplied by Dr. S. Dilworth, Middlesex University, London, UK), anti-PP2A-demethylated C subunit (clone 4b7, Merck-Millipore), and anti-vinculin (clone hVIN-1, Sigma-Aldrich). After washing in TBS/0.1% Tween-20, the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies (Dako for anti-mouse and Cell Signaling for anti-rabbit) and developed using Western Bright ECL (Advansta) on the ImageQuant LAS4000 scanner (GE Healthcare). All densitometric quantifications were performed with Image Studio Lite software (version 5.2).

2.3 PP2A activity assays

After HA pull-down, beads were washed once more with 20 mM Tris HCl (pH 8.0) and 1 mM DTT (Tris-DTT) and finally resuspended in 80 μ l Tris-DTT solution. All assays were performed with 35 μ l of this phosphatase suspension and 10 μ l of 2 mM stock of K-R-pT-I-R-R phospho-peptide for 10–20 min at 30°C (still in the linear range of the assay). The released free phosphate was determined by the addition of BIOMOL Green (catalog no. BMLAK111-0250, Enzo). After 30 min of incubation at RT, absorbance at 620 nm was measured in a multi-channel spectrophotometer. We subsequently obtained specific phosphatase activity by correcting the measured absorbance for the input of HA-tagged Ca, as determined by immunoblotting with anti-HA antibodies and signal quantification by Image Studio Lite software (version 5.2).

2.4 Statistics

Statistical analysis of biochemical data was assessed with unpaired Student's *t*-test or with one-sample Student's *t*-test in which the data were compared with WT values that were set at 100% in each experimental replicate. *p* values below 0.05 were considered significant.

2.5 Protein stability prediction and variant modeling

Protein stabilities were calculated using the FoldX force field (Schymkowitz et al., 2005). For details of the FoldX calculations, see the reference. The force field was run in a command line interface. In brief, the crystal structure of PPP2CA, as determined within the PP2A-B56 γ heterotrimer (Cho and Xu, 2007), was used as the input for the initial refinement step performed by the

RepairPDB command in FoldX. This produced an energy-minimized PDB file where the BuildModel command could then be used to incorporate the Cys196Arg substitution while keeping steric hindrances and energies at a minimum. The output with the incorporated Arg196 substitution was then used for the AnalyseComplex command. This command ran $n = 3$ calculations and generated overall ΔG values associated with the WT and variant models, so that $\Delta\Delta G$ values could be calculated.

AlphaFold was used to predict the structure of the PPP2CA p.Cys196Arg mutant. The open source Google Colab version of AlphaFold2 (ColabFold) was used for model prediction (Mirdita et al., 2022). The output model from AlphaFold was superimposed on the crystal structure of WT PPP2CA (PDB ID: 2IAE) for analysis in PyMOL (root mean square deviation: 0.511).


3 Results

3.1 Clinical findings

The patient was the full-term product of an uncomplicated pregnancy. The birth weight and length were within normal limits (weight $z = -0.25$ and length $z = 0.89$ per WHO Girls 0–2 growth charts). There were early concerns for poor breastfeeding and failure to gain appropriate weight that resolved after changing to formula. The patient had torticollis in infancy that resolved with physical therapy and required a helmet for the resulting positional plagiocephaly. There were no other concerns in the neonatal period.

She had two unprovoked generalized tonic–clonic seizures at age 1.5 years and two additional generalized tonic–clonic seizures at age 3, associated with fever. She was placed on Tegretol from age 2–5 and remained seizure free until age 12 when she had a recurrence of tonic–clonic seizures. The seizures continued to increase in frequency despite medications, although she had required medication changes due to side effects, including excessive sedation and anxiety. The brain MRI completed at age 12 was normal.

There were concerns for developmental delay beginning at 6 months as the patient was not achieving developmental milestones as quickly as an older sibling, but early milestones were within normal limits. The patient sat independently at approximately 6 months and stood at 10–11 months. She was walking by 14 months of age. She said her first word at 12 months of age, but she communicated through pointing/grunting until she started using sentences at age 3.5 years. She toilet trained at 3.5 years but continued to have nocturnal bed wetting until age 9. Academic difficulty was noted early, with particular difficulty with speech, articulation, and reading. She was initially in a common classroom environment but



eventually required full-time special education assistance. At age 11, full-scale IQ testing showed an IQ of 83. Developmental testing at that time led to the diagnosis of autism, and she was noted to have extremely low adaptive functioning. She is currently 18 years old and reads at a 5th-grade level with difficulty. She has difficulty with social interactions, has restrictive and repetitive behaviors, and is hyper- or hypo-reactive to sensory input. She developed selective mutism and significant anxiety as a child (<10 years of age), requiring medication, as well as skin-picking behaviors. She also has a history of significant textural food aversion developing around the same age leading to hospitalization at age 16 for malnutrition in the setting of avoidant restrictive food intake disorder. She had improvement in weight gain with Mirtazapine. The patient is also nearsighted, while her hearing ability is within normal limits. At the gastrointestinal level, she suffers from constipation and GERD.

3.2 Family history

To reveal a potential familial cause, the patient’s family history was collected. The patient was of northern European ancestry. Her father (III-4) has a mildly enlarged aorta, but the immediate family is otherwise healthy (Figure 1). There is a distant paternal granduncle with suspected intellectual disability (II-1), and his son (III-1) is suspected to have autism. Maternal

grandfather (II-8) had bipolar disorder and Lewy body dementia vs. Parkinson’s disease when he died at age 67. There is a maternal granduncle (II-6) with bipolar disorder and a maternal granduncle (II-6) with Alzheimer’s disease, as did the patient’s maternal great-grandmother (I-6). There is a maternal first cousin (IV-6) and first cousin once removed (V-3) with L-carnitine deficiency. There is a maternal first cousin with suspected autism (V-1) (Figure 1).

3.3 Genetics

The patient was first evaluated by Medical Genetics at age 10 due to a tall, thin body habitus and re-evaluated at age 16 due to autism and epilepsy. At the most recent evaluation, she was noted to have a slight build (weight $z = -0.86$, height $z = -0.3$) with relative microcephaly ($z = -1.48$ Nellhaus Girls). The exam was significant for a thin body habitus as well as a long face, deep-set eyes, thin alae nasi with prominent nasal tip, and wide mouth with a prominent chin (Figure 2). She had mild limitation of elbow extension and bilateral mild pes planovalgus. Both hands had proximally placed thumbs, and the feet had broad hallices bilaterally (Figure 2). A neurologic exam showed normal cranial nerves, normal tone (no hypotonia), normal reflexes, and normal coordination/gait. The echocardiogram showed a mildly dilated ascending aorta, likely secondary to low body surface area (2.64 cm, $z = 2.4$). The workup included normal ammonia and chromosomal microarray. The karyotype revealed a



FIGURE 2

Photographs of the patient. Facial features of this patient (age 18 years, 1 month) include a long face, deep set eyes, thin alae nasi (red arrows) with prominent nasal tip, and wide mouth with prominent chin (black arrows). Bilateral hands have proximally placed thumbs (green arrows), and bilateral feet have broad halluces (purple arrows). At the time that photographs were taken, the patient had a fungal nail infection that was healing. She also had marks of her socks on her feet. Informed consent was provided by the parents.

chromosome 9p12q13 inversion thought to be benign. An extensive autism/intellectual disability gene sequencing panel was negative. She subsequently underwent trio clinical exome and mitochondrial DNA sequencing that revealed a *de novo* heterozygous variant in *PPP2CA* (c.586T>C, p.Cys196Arg), as well as biallelic variants in *SKIV2L* [paternally inherited c.2932G>A (p.G978R) and maternally inherited c.3254G>A (p.S1085N)].

Pathogenic variants in *SKIV2L* are associated with severe, intractable diarrhea with onset in the first few weeks of life (OMIM: #614602, reviewed in Fabre et al., 2012). While the patient had compound heterozygous variants in the *SKIV2L* gene that are classified as variants of uncertain significance by ACMG criteria (Richards et al., 2015), the patient had no history of intractable diarrhea. Variants in *SKIV2L* are not associated with autism, intellectual disability, seizures, or the patient's facial or




FIGURE 3

Localization of the p.Cys196Arg variant in the catalytic PP2A C α subunit. **(A)** Domain organization of the catalytic PP2A C α subunit. The p.Cys196Arg variant in PP2A C α is indicated in purple (bold), and other conserved residues in the catalytic subunit are also shown. Red amino acids denote metal binding, while blue amino acids denote phosphate binding. The loop switch is indicated in orange [figure adapted from [Vanevnde et al. \(2022\)](#)]. **(B)** Structure of the catalytic PP2A C α subunit. The structure was generated based on PP2A-B56y1 crystallographic data, using PDB code 2IAE ([Cho and Xu, 2007](#)) and Molsoft MolBrowser 3.9-2b software (ICM-Browser-Pro). The catalytic C α subunit is shown in green, the A subunit in sky-blue, and the B56y1 subunit in yellow. The p.Cys196Arg residue is indicated in purple, while the residues of the loop switch are colored orange.

musculoskeletal features. These variants were therefore considered unlikely to contribute to her phenotype.

In contrast, the *PPP2CA* p.Cys196Arg variant was predicted to be disease-causing by MutationTaster ([Schwarz et al., 2014](#)). This may be explained by the central position of the mutation in the catalytic core domain of the protein ([Figure 3A](#)), and hence, different enzyme features might be affected, including the formation and stabilization of secondary structures (helices and strands) and metal binding ([Cho and Xu, 2007](#)). Moreover, the cysteine residue at position 196 is positioned immediately adjacent to the loop switch (amino acids 183–195), which is known to determine the conformation of the active site and the binding of catalytic metal ions ([Jiang et al., 2013](#)) ([Figures 3A,B](#)). This prompted us to further analyze the biochemical properties of this variant in more detail.

3.4 Molecular findings

For functional studies, wild-type C α (C α WT) or the C α p.Cys196Arg variant were ectopically expressed as N-terminally HA-tagged fusion proteins in human embryonic kidney cells (HEK293T).

To determine potential expression issues of the variant, equal amounts of HA-tagged WT and variant C α expression plasmids were co-transfected with an equal amount of GFP (green fluorescent protein) expression plasmid, allowing us to determine WT and variant expression levels relative to an internal (vinculin expression) and transfection efficiency control (GFP expression). Immunoblot analysis of total protein lysates of transfected cells with anti-HA, anti-vinculin, and anti-GFP antibodies consistently showed comparable expression of C α WT and C α p.Cys196Arg ([Figure 4](#)).

Next, HA-tagged proteins were isolated from transfected cell lysates on anti-HA-agarose beads, and subjected to three assays ([Reynhout et al., 2019](#)): 1) binding to endogenous PP2A A subunit; 2) measurement of catalytic activity; and 3) determination of carboxy-terminal methylation—a well-established post-translational modification of C α that determines its ability to form (specific) holoenzyme complexes ([Janssens et al., 2008](#); [Sents et al., 2013](#)).

First, the presence of the A subunit in complex with HA-tagged C α WT or p.Cys196Arg was analyzed by anti-A immunoblotting. Binding of the structural A subunit to the C α p.Cys196Arg variant was found moderately impaired compared to C α WT ([Figure 5](#)). Second, the intrinsic catalytic activity of both proteins was determined by incubating the anti-HA beads in complex with C α




FIGURE 4

Assessment of variant expression in HEK293T cells. Equal amounts of HA-tagged WT and variant Ca expression plasmids were co-transfected with an equal amount of GFP (green fluorescent protein) expression plasmid. Presence of HA-tagged Ca, GFP and vinculin in the lysates was assessed by anti-HA, anti-GFP, and anti-vinculin immunoblotting, respectively. Left panel: immunoblot from a representative experiment. As a negative control (Neg Ctr), pMB001 vector without insert was co-transfected with a GFP expression plasmid. Right panel: graph displaying expression levels of HA-tagged Ca WT or Ca p.Cys196Arg corrected to an internal (vinculin expression) and transfection efficiency (GFP expression) control. Results represent the average value \pm SD of the ratios of the corrected HA signal to the corrected GFP signal in relation to the values of WT Ca (set at 100% in each experiment, dotted line). An unpaired *t* test was used for analyzing statistical significance ($n = 3$).




FIGURE 5

Binding of PP2A Ca p.Cys196Arg to the structural A subunit. HA-tagged Ca WT and p.Cys196Arg proteins were purified from transfected HEK293T cells by HA-pulldown. Presence of endogenous A subunit in the complexes was measured by anti-HA immunoblotting. Left panel: immunoblot from a representative experiment. As a negative control (Neg Ctr) pMB001 vector without insert (expressing only HA tag) was used. Right panel: graph displaying quantified values of A subunit binding. Results represent the average value \pm SD of the ratios of the quantified anti-A signal to the quantified anti-HA signal in relation to those values of Ca WT (set at 100% in each experiment, dotted line). An unpaired *t* test was used for analyzing statistical significance ($n = 3$; ****, $p \leq 0.0001$).

WT or p.Cys196Arg with a generic phospho-peptide substrate (K-R-pT-I-R-R) for 10–20 min at 30°C and measuring the release of free phosphate by BIOMOL Green. Results indicated that PP2A activity of the p.Cys196Arg variant was significantly decreased by >90% compared to WT (Figure 6A). Third, we assessed potential changes in carboxy-methylation of the Ca p.Cys196Arg variant by using commercially available anti-demethyl antibodies. HA-tagged Ca p.Tyr265Cys was used as a positive control of low methylation status (or: high demethylation) (Reynhout et al., 2019). Anti-demethyl immunoblots showed that carboxy-methylation levels of Ca p.Cys196Arg were similar to Ca WT, indicating that Ca p.Cys196Arg could still be properly methylated (Figure 6B). Taken together, we identified Ca p.Cys196Arg as a mutant with moderately decreased A subunit binding, severely compromised catalytic activity, and unaltered carboxy-methylation.

In a second experimental setup, the HA-tagged Ca WT and mutant cDNAs were co-expressed with several GFP-tagged PP2A B-type subunits in HEK293T cells to assess potential B subunit binding defects (Reynhout et al., 2019). The binding of Ca proteins in the GFP pulldowns was monitored by anti-HA immunoblotting. Although overall binding changes appeared mild, a diverse B-type subunit binding pattern was observed for Ca p.Cys196Arg, characterized by retained binding to B56 γ 1 and STRN3, whereas binding to B55 α , B56 α , B56 β , B56 δ , B56 ϵ , and PR72 was moderately, but statistically significantly decreased, compared to Ca WT (Figures 7A–D).

Thus, biochemical characterization of Ca p.Cys196Arg confirmed its pathogenicity, underscoring that the disease is most likely caused by a functional loss of PP2A Ca enzymatic activity, and being consistent with a loss-of-function pathogenic mechanism.




FIGURE 6

Phosphatase activity and carboxy-methylation of PP2A Cα p.Cys196Arg. **(A)** Phosphatase activity of the PP2A Cα p.Cys196Arg subunit. HA-tagged Cα WT and p.Cys196Arg proteins were isolated from transfected HEK293T cells by HA-pulldown. PP2A activity was measured on the K-R-pT-I-R-R phospho-peptide using BIOMOL Green. Specific PP2A activity was calculated via correction of the measured activities for the Cα inputs (anti-HA immunoblotting). Left panel: immunoblot data from a representative experiment. As a negative control (Neg Ctr) pMB001 vector without insert (expressing only HA tag) was used. Right panel: graph representing the average specific activity \pm SD for the Cα p.Cys196Arg variant in comparison to WT activity (set at 100% in each replicate, dotted line). An unpaired t test was used for statistical analysis ($n = 6$; ****, $p \leq 0.001$). **(B)** Carboxy-methylation status of PP2A Cα p.Cys196Arg. HA-tagged Cα WT and p.Cys196Arg proteins were purified from transfected HEK293T cells by HA-pulldown. PP2A C subunit methylation was assessed by immunoblotting with a demethyl-specific anti-C monoclonal antibody. PP2A Cα p.Tyr265Cys was used as a positive control for low carboxy-methylation status (hence, high demethyl) (Reynhout et al., 2019). Left panel: immunoblot from a representative experiment. As a negative control (Neg Ctr) pMB001 vector without insert (expressing only HA tag) was used. Right panel: graph displaying the average ratios of the quantified anti-demethyl signals over the quantified anti-HA signals \pm SD in comparison to the demethylation levels of Cα WT (set at 100% in each experiment, dotted line). An unpaired t test was used for statistical analysis ($n = 6$, except p.Tyr265Cys: $n = 1$).


4 Discussion

First reported in 2015–2019 (Fitzgerald et al., 2015; Houge et al., 2015; Reynhout et al., 2019), PP2A-related neurodevelopmental disorders (NDDs) represent a family of rare (neuro)developmental disorders, of which the clinical and molecular spectrum is still likely incomplete, and new diagnoses and variants are likely to further emerge in the near future. Here, we described a case of an 18-year-old girl with a novel *de novo* pathogenic *PPP2CA* variant, which almost certainly explains her clinical features.

So far, only 16 *PPP2CA*-affected individuals have been reported in literature (Reynhout et al., 2019), making *PPP2CA*, by far, the least frequently affected gene of the PP2A family. Based on that single publication, *PPP2CA*-affected cases show a rather heterogeneous clinical presentation, characterized by mild to profound ID and/or DD (100%), seizures (63%), brain abnormalities (67%), hypotonia (69%), ASD or other major behavior problems (47%), and mild to no facial or other dysmorphisms (Reynhout et al., 2019). The female teenager we report here fell well within this spectrum, albeit, clearly, at the milder end. She indeed presented with mild developmental delay, but higher intellectual functioning (IQ of 83 at age 11 years), had normal muscle tone, no brain abnormalities (MRI at age


12 years), and very mild dysmorphic features (Figure 2). On the other hand, she experienced tonic-clonic seizures already at age 1.5 years, and since age 12, these seizures continued to increase despite anti-epileptic medication. In addition, she had difficulty with social interactions, showed restrictive and repetitive behaviors, and was hyper- or hypo-reactive to sensory input, suggestive of autism spectrum disorder. She also developed selective mutism and significant anxiety as a child, as well as avoidant restrictive food intake, both of which required medication.

The biochemical characterization of her *de novo PPP2CA* variant, p.Cys196Arg, concurred with the rather moderate phenotype, as essentially, only a major intrinsic inhibition of PP2A catalytic activity was found, while PP2A methylation was not changed, and complex formation with other PP2A subunits was not (B β /STRN3, B56 γ 1) or barely affected (40% decrease for A, 25% decrease for B55 α , 80% decrease for B56 α , 75% decrease for B56 β , 40% decrease for B56 δ , and 50% decrease for B56 ϵ and B β /PR72). Cys196 is localized near the catalytic center of the C subunit, immediately adjacent to the loop switch (Jiang et al., 2013) (Figures 3A,B). We, thus, suspect that the substitution of the cysteine residue by an arginine affects the conformation of this loop, and



consequently, the conformation of the active site and/or binding of catalytic metal ions (Jiang et al., 2013). This conformational change may also further explain the slight decrease in A subunit binding (Jiang et al., 2013), observed for the variant (Figure 5). To further underscore these hypotheses, we used two structure prediction algorithms: FoldX (Schymkowitz et al., 2005) and AlphaFold (Jumper et al., 2021). FoldX force field calculations to determine changes in the stability of Ca p.Cys196Arg revealed that the incorporation of Arg at this position results in a positive ΔG shift of 6.45 ± 3.06 kcal/mol, suggesting an increased destabilization of the protein compared to WT (Figure 8A). Using AlphaFold modeling, we observed that residues 185–194 corresponding to the loop switch were pushed farther from the active site. The largest shift involved His191 (1.3 Å), most likely due to a charge repulsion from Arg196 (Figure 8B). Moreover, we observed that the active site formed by residue side chains of Asp57, His59, Asp85, Asn117, and His241, was larger in the Ca p.Cys196Arg variant (Figure 8C). Based on the AlphaFold prediction, this conformational change is due to Asp57 bending away, along with shifts in His118 and His241 (Figure 8C). Thus, a more open active site with residues such as

His59, His118, and His241 pushed astray may adversely affect the proper binding of catalytic metal ions, and thereby impair catalytic activity, as observed in our phosphatase activity assays (Figure 6A). Alternatively, but less likely, Cys196 might be one of ten Cys residues in the Ca subunit that contribute to increased PP2A activity under reducing conditions (Foley and Kintner, 2005; Foley et al., 2007), and hence, its substitution into arginine may in part disturb that regulation. However, unlike other reported pathogenic *PPP2CA* variants with significantly impaired catalytic activity (p.Asp88Gly, p.Tyr127Cys and p.Tyr265Cys) (Reynhout et al., 2019), Carboxy-methylation of p.Cys196Arg appeared largely normal (Figure 6B), consistent with the observed lack of any major B-type subunit binding defects (Figure 7). Therefore, the molecular profile of the p.Cys196Arg variant we found here perhaps best resembles that of the only reported recurrent *PPP2CA* variant so far, p.His191Arg, which resides in the middle of the loop switch (Jiang et al., 2013; Reynhout et al., 2019) (Figure 3A). The p.His191Arg variant indeed showed decreased catalytic activity, unaffected Carboxy-methylation, and largely unaffected A- and B-type subunit binding, except for B56 δ (severely decreased binding, 14%) and B γ /STRN3 (increased binding, 651%) (Reynhout et al., 2019).



Thus, we should conclude that the observed pattern of biochemical impairments of the p.Cys196Arg variant appears rather unique amongst the currently reported *PPP2CA* variants, but concurring very well with the moderately affected clinical profile of the patient. Although the family pedigree of the girl did show some relatives with intellectual disability or autism, we can almost certainly attribute her condition to this new, pathogenic, *de novo PPP2CA* variant, and not to any other familial, genetic cause. We also did not consider the compound heterozygous *SKIVL2* variants as pathogenic, given the very different clinical image and lack of phenotypic fit with the reported *SKIVL2*-related trichoshepatoenteric syndrome ([Fabre et al., 2012](#)).

The current case report further highlights that we likely have not yet seen the full clinical and molecular spectrum of the *PPP2CA*-related disorder and that yet more patients with additional new variants might be encountered and diagnosed in the near future, especially at the milder end of the spectrum. Future research should not only keep an eye on such new diagnoses, but should also start focusing on studying the

functional implications of *PPP2CA* mutations on brain development and neuronal signaling. For these purposes, the generation of appropriate cell and *in vivo* models of these disorders is eagerly awaited.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.

Ethics statement

Ethical review and approval was not required for the study on human participants in accordance with the local legislation and institutional requirements. The patients/participants provided their written informed consent to participate in this study. Written informed consent was obtained from the individual(s)

for the publication of any potentially identifiable images or data included in this article.

Author contributions

IV and LL performed biochemical assays and analyzed data; SR generated the mutant; SP and KK provided clinical and genetic data; AM modeled the stability and structural changes in the variant, supervised by CU; and IV, SP, AM, VJ, and KK wrote and revised the manuscript.

Funding

The authors acknowledge the following funding agencies for their support: the Research Foundation-Flanders (FWO-Vlaanderen) (to IV and SR) and the Jordan's Guardian Angels Foundation (to VJ). S.S.P was funded through an NIH Postdoctoral Fellowship T32 HL125241.

References

- Cho, U. S., and Xu, W. (2007). Crystal structure of a protein phosphatase 2A heterotrimeric holoenzyme. *Nature* 445, 53–57. doi:10.1038/nature05351
- Douzgou, S., Janssens, V., and Houge, G. (2022). “PPP2R1A-Related neurodevelopmental disorder,” in *GeneReviews*[®] [internet]. Editors M. P. Adam, D. B. Everman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, L. J. H. Bean, et al. (Seattle (WA): University of Washington, Seattle).
- Fabre, A., Charroux, B., Martinez-Vinson, C., Roquelaure, B., Odul, E., Sayar, E., et al. (2012). *SKIV2L* mutations cause syndromic diarrhea, or trichohepatoenteric syndrome. *Am. J. Hum. Genet.* 90, 689–692. doi:10.1016/j.ajhg.2012.02.009
- Fitzgerald, T. W., Gerety, S. S., Jones, W. D., Van Kogelenberg, M., King, D. A., McRae, J., et al. (2015). Large-scale discovery of novel genetic causes of developmental disorders. *Nature* 519, 223–228. doi:10.1038/nature14135
- Foley, T. D., and Kintner, M. E. (2005). Brain PP2A is modified by thiol-disulfide exchange and intermolecular disulfide formation. *Biochem. Biophys. Res. Commun.* 330, 1224–1229. doi:10.1016/j.bbrc.2005.03.108
- Foley, T. D., Petro, L. A., Stredny, C. M., and Coppa, T. M. (2007). Oxidative inhibition of protein phosphatase 2A activity: Role of catalytic subunit disulfides. *Neurochem. Res.* 32, 1957–1964. doi:10.1007/s11064-007-9394-x
- Haesen, D., Asbagh, L. A., Derua, R., Hubert, A., Schrauwen, S., Hoorn, Y., et al. (2016). Recurrent *PPP2R1A* mutations in uterine cancer act through a dominant-negative mechanism to promote malignant cell growth. *Cancer Res.* 76, 5719–5731. doi:10.1158/0008-5472.CAN-15-3342
- Houge, G., Haesen, D., Vissers, L. E. L. M., Mehta, S., Parker, M. J., Wright, M., et al. (2015). B56δ-related protein phosphatase 2A dysfunction identified in patients with intellectual disability. *J. Clin. Invest.* 125, 3051–3062. doi:10.1172/JCI79860
- Janssens, V., and Goris, J. (2001). Protein phosphatase 2A: A highly regulated family of serine/threonine phosphatases implicated in cell growth and signalling. *Biochem. J.* 353, 417–439. doi:10.1042/0264-6021:3530417
- Janssens, V., Jordens, J., Stevens, I., Van Hoof, C., Martens, E., De Smedt, H., et al. (2003). Identification and functional analysis of two Ca²⁺-binding EF-hand motifs in the B'/PR72 subunit of protein phosphatase 2a. *J. Biol. Chem.* 278, 10697–10706. doi:10.1074/jbc.M211717200
- Janssens, V., Longin, S., and Goris, J. (2008). PP2A holoenzyme assembly: In cauda venenum (the sting is in the tail). *Trends Biochem. Sci.* 33, 113–121. doi:10.1016/j.tibs.2007.12.004
- Jiang, L., Stanevich, V., Satyshur, K., Kong, M., Watkins, G. R., Wadzinski, B. E., et al. (2013). Structural basis of protein phosphatase 2A stable latency. *Nat. Commun.* 4, 1699. doi:10.1038/ncomms2663
- Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., et al. (2021). Highly accurate protein structure prediction with AlphaFold. *Nature* 596, 583–589. doi:10.1038/s41586-021-03819-2
- Lambrecht, C., Haesen, D., Sents, W., Ivanova, E., and Janssens, V. (2013). Structure, regulation, and pharmacological modulation of PP2A phosphatases. *Methods Mol. Biol.* 1053, 283–305. doi:10.1007/978-1-62703-562-0_17
- Lenaerts, L., Reynhout, S., Verbinnen, I., Laumonier, F., Toutain, A., Bonnet-Brilhault, F., et al. (2020). The broad phenotypic spectrum of *PPP2R1A*-related neurodevelopmental disorders correlates with the degree of biochemical dysfunction. *Genet. Med.* 23, 352–362. doi:10.1038/s41436-020-00981-2
- Loveday, C., Tatton-Brown, K., Clarke, M., Westwood, I., Renwick, A., Ramsay, E., et al. (2015). Mutations in the PP2A regulatory subunit B family genes *PPP2R5B*, *PPP2R5C* and *PPP2R5D* cause human overgrowth. *Hum. Mol. Genet.* 24, 4775–4779. doi:10.1093/hmg/ddv182
- Mirdita, M., Schütze, K., Moriawaki, Y., Heo, L., Ovchinnikov, S., and Steinegger, M. (2022). ColabFold: Making protein folding accessible to all. *Nat. Methods* 19, 679–682. doi:10.1038/s41592-022-01488-1
- Mirzaa, G., Foss, K., Nattakom, M., and Chung, W. (2019). “*PPP2R5D*-Related neurodevelopmental disorder,” in *GeneReviews*[®] [internet]. Editors M. P. Adam, D. B. Everman, G. M. Mirzaa, R. A. Pagon, S. E. Wallace, L. J. H. Bean, et al. (Seattle (WA): University of Washington, Seattle).
- Oyama, N., Vaneynde, P., Reynhout, S., Pao, E., Timms, A., Fan, X., et al. (2022). The clinical, neuroimaging and molecular characteristics of *PPP2R5D* related neurodevelopmental disorders: An expanded series with functional characterization and genotype-phenotype analysis. *J. Med. Genet.* 2022, 108713. doi:10.1136/jmg-2022-108713
- Reynhout, S., and Janssens, V. (2019). Physiologic functions of PP2A: Lessons from genetically modified mice. *Biochim. Biophys. Acta. Mol. Cell Res.* 1866, 31–50. doi:10.1016/j.bbamcr.2018.07.010
- Reynhout, S., Jansen, S., Haesen, D., van Belle, S., de Munnik, S. A., Bongers, E. M. H. F., et al. (2019). *De novo* mutations affecting the catalytic Ca subunit of PP2A, *PPP2CA*, cause syndromic intellectual disability resembling other PP2A-related neurodevelopmental disorders. *Am. J. Hum. Genet.* 104, 357–156. doi:10.1016/j.ajhg.2019.01.003
- Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., et al. (2015). Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American college of medical genetics and Genomics and the association for molecular Pathology. *Genet. Med.* 17, 405–424. doi:10.1038/gim.2015.30

Acknowledgments

The authors thank the parents for their participation and contribution to the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Sandal, P., Jong, C. J., Merrill, R. A., Song, J., and Strack, S. (2021). Protein phosphatase 2A – structure, function and role in neurodevelopmental disorders. *J. Cell Sci.* 134, jcs248187. doi:10.1242/jcs.248187

Schwarz, J. M., Cooper, D. N., Schuelke, M., and Seelow, D. (2014). Mutationtaster2: Mutation prediction for the deep-sequencing age. *Nat. Methods* 11, 361–362. doi:10.1038/nmeth.2890

Schymkowitz, J., Borg, J., Stricher, F., Nys, R., Rousseau, F., and Serrano, L. (2005). The FoldX web server: An online force field. *Nucleic Acids Res.* 33, W382–W388. doi:10.1093/nar/gki387

Sents, W., Ivanova, E., Lambrecht, C., Haesen, D., and Janssens, V. (2013). The biogenesis of active protein phosphatase 2A holoenzymes: A tightly regulated process creating phosphatase specificity. *FEBS J.* 280, 644–661. doi:10.1111/j.1742-4658.2012.08579.x

Shang, L., Henderson, L. B., Cho, M. T., Petrey, D. S., Fong, C. T., Haude, K. M., et al. (2016). *De novo* missense variants in *PPP2R5D* are associated with intellectual disability, macrocephaly, hypotonia, and autism. *Neurogenetics* 17, 43–49. doi:10.1007/s10048-015-0466-9

Slupe, A. M., Merrill, R. A., and Strack, S. (2011). Determinants for substrate specificity of protein phosphatase 2A. *Enzyme Res.* 2011, 398751. doi:10.4061/2011/398751

Vaneynde, P., Verbinnen, I., and Janssens, V. (2022). The role of serine/threonine phosphatases in human development: Evidence from congenital disorders. *Front. Cell Dev. Biol.* 10, 1030119. doi:10.3389/fcell.2022.1030119

Verbinnen, I., Vaneynde, P., Reynhout, S., Lenaerts, L., Derua, R., Houge, G., et al. (2021). Protein Phosphatase 2A (PP2A) mutations in brain function, development, and neurologic disease. *Biochem. Soc. Trans.* 49, 1567–1588. doi:10.1042/BST20201313